Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities
Biomolecules · 2026
DOI: 10.3390/biom16101422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Martina Perin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Torino, Piazza Nizza 44/bis, 10126 Torino, Italy. Hauptthemen laut MEDLINE: Mitochondria, Sarcoma, Drug Resistance, Neoplasm. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Fondazione CRT, Fondazione Cassa di Risparmio di Torino.
Abstract (Originalsprache)
Sarcomas are a heterogeneous group of tumors accounting for 1% and 15% of adult and child cancers, respectively. Because of their high genomic instability, biological heterogeneity and metastatic potential, sarcomas are challenging to treat. Current treatments rely on surgical resection combined with chemotherapy and radiotherapy; however, the outcome remains poor in advanced or recurrent stages. As in many other solid tumors, a growing body of evidence in sarcoma also highlights the central role of metabolic reprogramming in progression and treatment resistance. Mitochondria are key players in bioenergetic processes, redox balance and apoptotic signaling. This review will discuss the latest findings demonstrating that alterations in mitochondrial energetic metabolism, mitochondrial dynamics and mitochondria-dependent pro-apoptotic signaling promote malignant transformation, progression, immune evasion and resistance to treatments in soft-tissue and bone sarcomas. Mitochondrial pleiotropism, however, can unveil new vulnerabilities. Several compounds disrupting mitochondrial respiration, increasing the production of mitochondrial reactive oxygen species, and triggering mitochondrial-dependent apoptosis achieved promising results at a preclinical level as new anti-sarcoma agents, alone or combined with chemotherapy, radiotherapy or immunotherapy. Knowing the multifaceted roles of mitochondria in sarcoma progression and resistance may be the first step toward new treatment tools, noteworthy for future clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Torino, Piazza Nizza 44/bis, 10126 Torino, Italy.
- Molecular Biotechnology Center "Guido Tarone", Piazza Nizza 44/bis, 10126 Torino, Italy.
ORCID-Profile: Martina Perin, Alberto Lipani, Joanna Kopecka, Chiara Riganti
Förderung
- Italian Association for Cancer Research
- Fondazione CRT
- Fondazione Cassa di Risparmio di Torino
Zitieren
APA
Perin, M., Lipani, A., Loffa, M., Todesco, A. M., Kopecka, J., & Riganti, C. (2026). Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities. Biomolecules. https://doi.org/10.3390/biom16101422
Vancouver
Perin M, Lipani A, Loffa M, Todesco AM, Kopecka J, Riganti C. Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities. Biomolecules. 2026. doi:10.3390/biom16101422
BibTeX
@article{Perin2026,
author = {Perin, Martina and Lipani, Alberto and Loffa, Marco and Todesco, Alberto Maria and Kopecka, Joanna and Riganti, Chiara},
title = {Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16101422}
}
EUVIMED